tirzepatide surmount-1 weight loss percent 72 weeks SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, Tirzepatide leads to weight reduction

Some studies suggest GLP-1 agonists may reduce serum uric acid through increased renal excretion and weight loss, though the effect is modest and not consistently replicated

JCI insight

Our approach is renowned for emphasizing education, safety, and personalized care, giving patients a clear understanding of how peptides influence the bodys natural systems

This regulatory effect dampens downstream inflammatory cascades and curtails prolonged DC-mediated immune activation, thereby alleviating colitis-associated mucosal damage [160]

Regulation and access

Klein, UNC Chapel Hill Lets celebrate these new insights and look forward to more evidence for improving outcomes in this vulnerable patient group